Risperidone Long-Acting Injection

Form: Long-Acting Injection

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes

Reference Brands: Risperdal Consta(US &EU)

Category: Antipsychotropic Drugs

Risperidone Long-Acting Injection, commonly marketed as Risperdal Consta, is a second-generation antipsychotic approved in both the US (FDA) and EU (EMA) for the treatment of schizophrenia and maintenance therapy in bipolar disorder. It is administered intramuscularly every two weeks and provides steady plasma levels, improving adherence in patients with chronic psychosis. The drug requires prior oral risperidone trial before initiating long-acting therapy. In the EU, it is approved under centralized and national procedures. In the US, it holds FDA approval under NDA. Its prolonged-release formulation is protected by a series of patents, though generic development has begun in select markets.